Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : OTC Shell Search and DD... -- Ignore unavailable to you. Want to Upgrade?

To: Tevyah who wrote (357)	2/14/1999 6:48:00 PM
From: P.S.N.	Read Replies (1) \| Respond to of 858

Tevyah, you mite want to go to Yahoo and check out the last sec filing it's about a year old but it mite be the reason, IMHO.The part that interests me is................................................ "In addition, research and development activities on new products continued. In December 1997, Ultrafem completed its first clinical study of a contraceptive product that combines BufferGel with SoftCup Technology. The BufferGel Phase I clinical trial in the U.S. has also been completed. The trial was sponsored by HIVNET, a unit of the National Institute of Health to test the safety and acceptability of BufferGel for use as a vaginal microbicide for preventing AIDS and other sexually transmitted diseases. Based on this trial, HIVNET has determined that BufferGel is sufficiently safe and acceptable to justify expanding the studies to four international sites; the first of these additional studies is underway in Malawi, Africa. BufferGel was developed by ReProtect, LLC scientists associated with Johns Hopkins University. Ultrafem has the worldwide licensing rights to BufferGel and intends to bring to market innovative vaginal products that combine the BufferGel and SoftCup technologies. " PSN